An interventional study of Non-surgical Periodontal Therapy (Scaling and Root Planing) and Saliva Collection in Periodontal Disease and Chronic Periodontitis (Disorder), sponsored by Ömer Faruk Okumuş. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Ömer Faruk Okumuş · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Chronic Periodontitis with a site in Turkey — 1 open to participants now, 1 under way, none of them phase 3. Chronic Periodontitis · Turkey.
Among the 26 studies in Chronic Periodontitis with a site in Turkey, this one is the 3rd largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2025, is one of 12 with no phase, and was the 24th registered.
378 studies on the registry are indexed under Chronic Periodontitis; 21 are open to participants now.
Browse Chronic Periodontitis studies →1 of the 26 studies in Chronic Periodontitis with a site in Turkey is open now. Recruiting first, the newest first:
Hacettepe University · Sites in Turkey
Ages 18–65
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 13 Chronic Periodontitis studies recruiting now, 7 (54%) set no upper age limit and 5 (38%) stop at 75 or younger; none take children under 18; 4 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2025.
This study's enrollment of 104 is above the median of 46 across 308 interventional studies indexed under Chronic Periodontitis.
Median enrollment 30 across the 15 interventional studies, 73 across the 11 observational. Of the 25 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 26 has an industry lead sponsor. The 10 most frequent:
Ömer Faruk Okumuş is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Ömer Faruk Okumuş has 1 study filed under Chronic Periodontitis — fewer than ten, so there is no comparison to draw.
1 of the studies in Chronic Periodontitis with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07452640Hacettepe UniversityVector® System vs Mini-Five Curettes in Non-Surgical Periodontal Therapy | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Chronic Periodontitis with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Periodontitis (gum inflammation) is a common disease worldwide. This study aims to investigate a novel biomarker, a protein called Mitofusin-1 (Mfn1), in saliva that may be associated with the severity of periodontitis and response to treatment. The study will include periodontally healthy individuals, individuals with mild to severe periodontitis, and smokers with severe periodontitis. Participants will receive saliva samples and undergo clinical periodontal examinations. Individuals with periodontitis will receive standard periodontal treatment, and changes in Mfn1 levels will be assessed 3 months after treatment. The study is expected to shed light on the potential utility of Mfn1 as a marker in the diagnosis and follow-up of periodontitis.
378 studies on the registry are indexed under Chronic Periodontitis; 21 are open to participants now.
This study's enrollment of 104 is above the median of 46 across 308 interventional studies indexed under Chronic Periodontitis.
Browse Chronic Periodontitis studies →Ömer Faruk Okumuş is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Compared within Chronic Periodontitis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Periodontal Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Healthy Control Group:
No clinical attachment loss. Probing depth ≤ 3 mm. No radiographic evidence of bone loss. Low gingival and plaque index scores.
For Mild Periodontitis Group:
Diagnosed with Stage I or II periodontitis according to the 2018 AAP/EFP classification.
Clinical attachment loss of 1-4 mm. Radiographic bone loss of ≤15-33%. Non-smoker.
For Severe Periodontitis Group:
Diagnosed with Stage III or IV periodontitis according to the 2018 AAP/EFP classification.
Clinical attachment loss ≥ 5 mm. Radiographic bone loss to the mid-advanced level of the root. Non-smoker.
For Severe Periodontitis with Smoking Group:
Meets all criteria for the Severe Periodontitis Group. Regular smoker (at least 10 cigarettes per day for a minimum of 5 years).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periodontally healthy individuals with no clinical attachment loss, probing depth ≤3 mm, no radiographic bone loss, and low gingival and plaque index scores.
Other: Saliva Collection
Non-smoking individuals diagnosed with Stage I-II periodontitis according to the AAP/EFP 2018 classification, with clinical attachment loss of 1-4 mm and ≤15-33% radiographic bone loss.
Procedure: Non-surgical Periodontal Therapy (Scaling and Root Planing) · Other: Saliva Collection
Non-smoking individuals diagnosed with Stage III-IV periodontitis according to the AAP/EFP 2018 classification, with clinical attachment loss ≥5 mm and radiographic bone loss to the mid-advanced level of the root.
Procedure: Non-surgical Periodontal Therapy (Scaling and Root Planing) · Other: Saliva Collection
Individuals who meet the criteria for the Severe Periodontitis Group and are also regular smokers (at least 10 cigarettes per day for a minimum of 5 years).
Procedure: Non-surgical Periodontal Therapy (Scaling and Root Planing) · Other: Saliva Collection
A standard periodontal treatment procedure that involves the removal of dental plaque and calculus (tartar) from the tooth surfaces and root pockets. This is followed by root planing to smooth the root surfaces, allowing the gingiva to heal and reattach to the tooth.
Collection of unstimulated whole saliva. Participants will be asked to allow saliva to pool in the floor of the mouth and then passively drool into a sterile collection tube. A total of 1.5 ml of saliva will be collected from each participant.
Salivary Mitofusin-1 (Mfn1) Concentration at Baseline
Mfn1 protein concentration in saliva measured using ELISA (ng/mL) at baseline in each study group.
Time frame: Baseline
Change in Salivary Mfn1 Concentration After Periodontal Therapy
Difference in salivary Mfn1 concentration (ng/mL) measured using ELISA at baseline and 3 months after non-surgical periodontal therapy in the periodontitis groups.
Time frame: Baseline and 3 months
Salivary Glutathione Peroxidase (GPx) Concentration
GPx enzyme activity measured in saliva by spectrophotometric colorimetric assay (U/L).
Time frame: Baseline
Salivary 8-Hydroxy-2'-Deoxyguanosine (8-OHdG) Concentration
8-OHdG concentration measured in saliva using ELISA (ng/mL).
Time frame: Baseline
Correlation Between Salivary Mfn1 Concentration and Probing Depth (PD)
Correlation coefficient (r) between salivary Mitofusin-1 (Mfn1) concentration measured by ELISA (ng/mL) and probing depth measured with a manual periodontal probe (mm).
Time frame: Baseline
Correlation Between Salivary Mfn1 Concentration and Clinical Attachment Level (CAL)
Correlation coefficient (r) between salivary Mitofusin-1 (Mfn1) concentration measured by ELISA (ng/mL) and clinical attachment level measured with a manual periodontal probe (mm).
Time frame: Baseline
Correlation Between Salivary Mfn1 Concentration and Plaque Index (PI)
Correlation coefficient (r) between salivary Mitofusin-1 (Mfn1) concentration measured by ELISA (ng/mL) and plaque index assessed using the Silness-Löe Plaque Index (%).
Time frame: Baseline
Correlation Between Salivary Mfn1 Concentration and Gingival Index (GI)
Correlation coefficient (r) between salivary Mitofusin-1 (Mfn1) concentration measured by ELISA (ng/mL) and gingival index assessed using the Löe-Silness Gingival Index (score).
Time frame: Baseline
Ran from Nov 2025 to primary completion in Apr 2026, 5 months.
Of 89 non-industry interventional studies with no phase under Chronic Periodontitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 24. This study's 5 months is below that.
Counting every sponsor, half of 90 studies reached it within 15 months; a quarter within 10 and three quarters within 24.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Feb 2026 → Apr 2026 and completion Nov 2026 → Jul 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ömer Faruk Okumuş